logo
Share SHARE
FONT-SIZE Plus   Neg

Santarus Says FDA Accepts Application Seeking Approval For Colon Drug Uceris

Biopharmaceutical company Santarus, Inc. (SNTS) on Wednesday said the United States Food and Drug Administration has accepted for filing its new drug application for Uceris tablets indicated for treatment of inflammatory bowel disease.

With the application, or NDA, the company seeks approval to market Uceris (budesonide) tablets 9 mg in the U.S. as a therapy to induce remission of mild to moderate active ulcerative colitis. The company anticipates the completion of the FDA's review or a response to the NDA by mid-October 2012.

Santarus will now pay $4 million to the co-developer of the drug, Cosmo Technologies Limited, a unit of Japan's Cosmo Pharmaceuticals S.p.A, in cash or Santarus stock at Cosmo's option.

Ulcerative colitis is a form of inflammatory bowel disease that produces inflammation and ulcers along the inside of the colon that could cause cramping, bloating, diarrhea, bleeding, fatigue, weight loss and frequent bowel movements. According to the Crohn's & Colitis Foundation of America, the chronic relapsing-remitting illness affects an estimated 1.4 million Americans.

Gerald Proehl, president and chief executive officer, stated, "Ulcerative colitis is a serious, chronic disease that typically starts to manifest in young adults with a long-term negative impact on the patient. We look forward to the potential to offer what we believe will be an important new therapeutic option to physicians and their patients to manage the symptoms of active ulcerative colitis."

Santarus shares closed Tuesday's regular trading session at $4.80, down $0.12 or 2.44 percent.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Federal investigators have closed their probe of a fatal crash that involved a Tesla Motors Inc. car eight months ago. The regulators said they have found no safety defects in the vehicle's automated driving system and that Tesla's Autopilot-enabled vehicles did not need to be recalled. Consumer goods giant Procter & Gamble Co. on Friday reported a profit for the second quarter that more than doubled from last year on a one-time gain and higher margins, while sales edged lower. Both revenue and core earnings per share for the quarter beat analysts' estimates. General Electric Company (GE) reported that its fourth-quarter Industrial operating plus Verticals EPS, a non-GAAP measure, decreased to $0.46 from $0.52 last year. Industrial operating plus Verticals earnings excluding gains & restructuring was $0.50 compared to $0.47. On average, 17 analysts polled...
comments powered by Disqus
Follow RTT